HEXB (Beta-Hexosaminidase Subunit Beta) Drug Discovery Landscape & Assay Solutions
- By admin
- 19 Aug 2026
- Comments
Market Intelligence for Sandhoff Disease Gene Therapy, Enzyme Replacement, and Pharmacological Chaperone Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HEXB drug discovery. Products include wild-type and mutant proteins (covering key dbSNP variants such as rs820878, rs11556045, and rs10805890), gene delivery lentivirus, benchmark antibodies, and siRNA sets. All proteins are expressed in HEK293 cells to ensure native glycosylation (M6P tagging) for lysosomal targeting.
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HEXB Recombinant Protein (WT & mutant variants, >95% purity, sequence verified, endotoxin <1 EU/µg) | View HEXB Products |
| Gene Delivery | HEXB Lentivirus Premade Particles (full-length ORF for stable cell lines) | View HEXB Products |
| Benchmark Ab | Anti-HEXB Recombinant Antibody (research grade, positive control for WB/ELISA) | View HEXB Products |
| Validator | HEXB siRNA Set (for knockdown verification and specificity checks) | View HEXB Products |
| Related Target: HEXA | HEXA (Alpha subunit) – forms functional heterodimer with HEXB | View HEXA Products |
| Related Target: GM2A | GM2 Activator Protein – essential cofactor for substrate presentation | View GM2A Products |
| Related Target: M6PR | Mannose-6-phosphate receptor – crucial for lysosomal uptake of recombinant enzyme | View M6PR Products |
Critical Assay Challenges Addressed by TarMart
| Assay Challenge | TarMart Advantage |
|---|---|
| Disease variant structural integrity | Recombinant mutant proteins (covering key dbSNP variants) with >95% purity, sequence verified by mass spec |
| Heterodimeric enzyme assembly | HEXA/HEXB co-expression validation proteins available |
| Lysosomal trafficking verification | HEK293 expression ensures native M6P glycosylation for authentic post-translational modifications |
| Pharmacological chaperone screening | High-stability mutant protein preparations for thermal shift and binding assays |
| Lack of reliable controls | Sequence-verified positive control antibodies and validated siRNA included |
Clinical Landscape & Future Outlook
The race for Sandhoff disease therapeutics is intensifying, with major players shifting focus from palliative care to genetic medicines. First-generation AAV gene therapies (e.g., TSHA-118) are entering Phase 1/2 trials. Next-wave R&D targets improved blood-brain barrier (BBB) penetration and pharmacological chaperones for mutation-specific rescue. Key challenges include CNS delivery, immunogenicity monitoring, and long-term safety.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV9) | Taysha Gene Therapies, Sio Gene Therapies | Sandhoff Disease, GM2 Gangliosidosis | Stable cell line construction (lentivirus for disease models); expression validation antibodies |
| Pharmacological Chaperones | Amicus Therapeutics, Protalix Biotherapeutics, Gain Therapeutics | Sandhoff Disease (missense mutations) | Mutant protein stability assays (purified variants covering key dbSNP mutations) |
| Enzyme Replacement | BioMarin, Ultragenyx (exploratory); Sanofi, Takeda | Peripheral Sandhoff symptoms; LSDs | Immunogenicity testing (high-purity antigen for ADA assays); cellular uptake assays (HEK293-expressed M6P-tagged proteins) |
| Substrate Reduction | Actelion (Johnson & Johnson) | GM2 Gangliosidosis (adjunct) | Enzyme activity panels (HEXB/HEXA kinetic assays) |
Live HEXB R&D Tracker
Cross-Sell Target Recommendations
Based on the GM2 ganglioside metabolism pathway, the following related targets are recommended for combined studies:
- HEXA: Dimerization partner; essential for functional Hex A enzyme.
- GM2A: Activator protein facilitating substrate presentation.
- M6PR: Receptor for M6P-dependent lysosomal uptake.
- NEU1: Neuraminidase-1 involved in sialic acid removal upstream of HEXB action.